Nafenopin

Nafenopin is a fibrate, a class of drugs that are primarily used to manage and treat dyslipidemia, specifically high levels of triglycerides in the blood. It was first synthesized in the 1960s and has been used in experimental studies to understand the role of peroxisome proliferator-activated receptors (PPARs) in lipid metabolism and carcinogenesis.

History

Nafenopin was first synthesized in the 1960s by the pharmaceutical company Eli Lilly. It was initially developed as a hypolipidemic agent, a drug used to lower the levels of lipids in the blood.

Pharmacology

Nafenopin is a member of the fibrate class of drugs, which are derivatives of fibric acid. Fibrates are primarily used to treat dyslipidemia, particularly high levels of triglycerides. They work by activating PPARs, a group of nuclear receptor proteins that regulate gene expression. By activating PPARs, fibrates increase the breakdown of fatty acids and reduce the production of triglycerides in the liver.

Role in Research

Nafenopin has been used in experimental studies to understand the role of PPARs in lipid metabolism and carcinogenesis. In particular, it has been used to study the role of PPARα, a subtype of PPARs, in the development of liver tumors in rodents. Nafenopin is a potent activator of PPARα, and studies have shown that chronic administration of nafenopin can lead to the development of liver tumors in rodents.

Side Effects

Like other fibrates, nafenopin can cause side effects such as gastrointestinal disorders, rash, and dizziness. In addition, long-term use of nafenopin has been associated with an increased risk of developing liver tumors in rodents.

See Also

• Fibrate
• Dyslipidemia
• Peroxisome proliferator-activated receptors
• Eli Lilly and Company

• 
  Nafenopin